Moreover, highly aggressive angiosarcomas exhibit considerable genomic plasticity, allowing them to activate alternative signaling pathways (e.g., MET, AXL, and MAS) (13, 16), thereby bypassing VEGFR inhibition by sunitinib. This evidence concerns the gene KDR and angiosarcoma.